検索
Urogen Pharma Ltd
URGNウォッチリストに追加
43.490USD
+1.750+4.19%
終値 09-16 16:00（ET）
2.13B時価総額
損失額直近12ヶ月PER
詳細情報 Urogen Pharma Ltd 企業名
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltd プロフィール
企業コードURGN
会社名Urogen Pharma Ltd
上場日May 04, 2017
最高経営責任者「CEO」Barrett (Elizabeth A)
従業員数235
証券種類Ordinary Share
決算期末May 04
本社所在地9 Ha'ta'asiya St
都市RA'ANANA
証券取引所NASDAQ OMX - NASDAQ BASIC
国Israel
郵便番号4365007
電話番号97297707601
ウェブサイトhttps://www.urogen.com/
企業コードURGN
上場日May 04, 2017
最高経営責任者「CEO」Barrett (Elizabeth A)
Urogen Pharma Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
53.14K
+3.42%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer
Chief Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
53.14K
+3.42%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer
Chief Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
よくある質問
Urogen Pharma Ltdの上位5名の株主は誰ですか？
Urogen Pharma Ltdの上位5名の株主は以下のとおりです。Dr. Arie S. Belldegrun, M.D.
Urogen Pharma Ltd（URGN）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Urogen Pharma Ltdの株式を保有している機関は349社あり、保有株式の総市場価値は約46.29Mで、全体の95.00%を占めています。2025Q4と比較して、機関の持ち株は-15691017.00増加しています。
Urogen Pharma Ltdの最大の収益源は何ですか？
2026Q1において、Zusduri部門がUrogen Pharma Ltdにとって最大の収益を生み出しており、その金額は50.43Mで、全収益の69.60%を占めています。